John Rother
John Rother
cumulative effect increases moving price rate row sixth twice year
It's moving in the right direction. I will say that. But this is the sixth year in a row of price increases that are at least twice the rate of inflation, so it has a cumulative effect that I think is pretty serious.
counteract discount full hurting impact none price prices programs
Still, none of these discount programs can counteract the full impact of these price increases. Even with the discounts, these prices are hurting people.
coverage joining people rush
There's no need to rush in, but most people will probably be better off getting the coverage than not joining up.
faster inflation prices
Drug prices are going up faster than inflation and we need to do more to keep them affordable.
assisted becoming changing clear create hopefully label living matter popular sign standard
Assisted living is becoming so popular that everyone's kind of changing the sign on their door, no matter what they provide. We thought it was important to create a clear standard ... so that hopefully the label of assisted living won't be used in a way to mislead people.
bipartisan path
I'm cautiously optimistic. I think we can see a path to a bipartisan bill.
concerned industry patients
I think the industry is more concerned about shareholders than they are about the patients who take the pills.
ability bringing continued earnings emphasized four health individual normal pass pensions people pillars ready retirement second social terms third
We really need to think about four pillars for retirement. ... The first pillar is Social Security. The second is individual pensions or savings. The third is health insurance, very important. And the fourth, surprisingly, is the continued ability to earn, because many people are going to need to find some way of bringing in earnings after they pass normal retirement age, and we think that that should be more and more emphasized in terms of getting ready for that possibility.
makers true wish
We just wish the same kind of self-restraint could be true for the makers of brand-name drugs.